Cullmann W
F. Hoffmann-La Roche Ltd., Pharma Division/Preclinical Research, Basel, Switzerland.
Chemotherapy. 1993;39(1):13-21. doi: 10.1159/000238968.
The susceptibility of approximately 4,200 fresh clinical isolates to eleven different orally available compounds was assessed in ten Italian microbiology institutions during summer 1991. A standardized microdilution system including all the material necessary was employed to assess the antibacterial activity of ampicillin, ampicillin plus sulbactam, amoxicillin plus clavulanic acid, cefadroxil, cephalexin, cefaclor, cefuroxime, cefetamet, doxycycline, erythromycin, and clindamycin. The amino-penicillins (including the beta-lactamase inhibitor combinations) were highly active against the streptococci, whereas cefetamet was the most active compound against Enterobacteriaceae, exhibiting good activity against the streptococci as well. The analysis of distribution of susceptibility revealed that there is a good discrimination between susceptible and resistant strains for cefetamet in any case, whereas the discrimination is low for the aminopenicillin/inhibitor combinations and the older cephalosporins in at least some of the gram-negative species.
1991年夏季，在意大利的十家微生物学机构中，对约4200株新鲜临床分离株对11种不同口服可用化合物的敏感性进行了评估。采用包括所有必要材料的标准化微量稀释系统，评估氨苄西林、氨苄西林加舒巴坦、阿莫西林加克拉维酸、头孢羟氨苄、头孢氨苄、头孢克洛、头孢呋辛、头孢他美、多西环素、红霉素和克林霉素的抗菌活性。氨基青霉素（包括β-内酰胺酶抑制剂组合）对链球菌具有高度活性，而头孢他美是对肠杆菌科最具活性的化合物，对链球菌也表现出良好活性。敏感性分布分析表明，无论何种情况，头孢他美对敏感菌株和耐药菌株都有很好的区分，而在至少一些革兰氏阴性菌中，氨基青霉素/抑制剂组合和较老的头孢菌素的区分度较低。
